公司資料
Fennec Pharmaceuticals Inc. 股價、新聞與催化劑
- 股票代碼:
- FENC
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
11.83 USD (+0.94%)
收盤價
最後更新: 2026年8月17日
347M USD
市值
股價為何變動
As of Aug 17, 2026, FENC closed up 0.94% at $11.83. No new same-company headline was identified in the current news window.
公司概覽
Ototoxicity Prevention Company
Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy.
Pediatric Commercial Foundation
PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through an oncology sales organization and the Fennec HEARS patient-services hub.
Expansion into Older Patients
Investigator-sponsored studies are evaluating PEDMARK in adolescent, young adult, and adult patients receiving cisplatin for head and neck, testicular, cervical, and other cancers.
未來催化劑
- Clinical data from investigator-sponsored PEDMARK studies in additional age groups and tumor types are expected to define potential expansion opportunities.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。